Last reviewed 2026-04-23 · How we verify

Evolocumab AMD

Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.

Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood. Used for Age-related macular degeneration (AMD) — investigational indication in Phase 3.

At a glance

Mechanism of action

PCSK9 normally binds to LDL receptors and causes their degradation, reducing the cell's ability to remove LDL cholesterol from circulation. By inhibiting PCSK9, evolocumab prevents this degradation, enabling hepatic cells to maintain higher numbers of functional LDL receptors on their surface. This results in substantially increased uptake and clearance of LDL cholesterol from the bloodstream, leading to significant reductions in LDL-C levels.

Approved indications

• Age-related macular degeneration (AMD) — investigational indication in Phase 3

Common side effects

• Injection site reactions
• Nasopharyngitis
• Upper respiratory tract infection

Key clinical trials

• Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Evolocumab AMD CI brief — competitive landscape report
• Evolocumab AMD updates RSS · CI watch RSS
• Amgen portfolio CI